Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Conmed Corp has a consensus price target of $86.11 based on the ratings of 9 analysts. The high is $141 issued by Keybanc on July 27, 2023. The low is $55 issued by Stifel on April 28, 2025. The 3 most-recent analyst ratings were released by Needham, JP Morgan, and Wells Fargo on June 12, 2025, May 1, 2025, and May 1, 2025, respectively. With an average price target of $58.67 between Needham, JP Morgan, and Wells Fargo, there's an implied 6.46% upside for Conmed Corp from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/12/2025 | Buy Now | 10.69% | Needham | Mike Matson70% | $61 → $61 | Downgrade | Buy → Hold | Get Alert |
05/01/2025 | Buy Now | 5.25% | JP Morgan | Robbie Marcus66% | $70 → $58 | Maintains | Neutral | Get Alert |
05/01/2025 | Buy Now | 3.44% | Wells Fargo | Vik Chopra44% | $70 → $57 | Maintains | Equal-Weight | Get Alert |
05/01/2025 | Buy Now | 10.69% | Needham | Mike Matson70% | $91 → $61 | Maintains | Buy | Get Alert |
04/28/2025 | Buy Now | -0.19% | Stifel | Rick Wise63% | $75 → $55 | Downgrade | Buy → Hold | Get Alert |
02/06/2025 | Buy Now | 36.1% | Stifel | Rick Wise63% | $72 → $75 | Maintains | Buy | Get Alert |
02/06/2025 | Buy Now | 27.03% | Wells Fargo | Vik Chopra44% | $74 → $70 | Maintains | Equal-Weight | Get Alert |
02/06/2025 | Buy Now | 65.13% | Needham | Mike Matson70% | $97 → $91 | Maintains | Buy | Get Alert |
02/06/2025 | Buy Now | 27.03% | JP Morgan | Robbie Marcus66% | $85 → $70 | Downgrade | Overweight → Neutral | Get Alert |
10/31/2024 | Buy Now | 76.02% | Needham | Mike Matson70% | $97 → $97 | Reiterates | Buy → Buy | Get Alert |
10/04/2024 | Buy Now | 76.02% | Needham | Mike Matson70% | $97 → $97 | Reiterates | Buy → Buy | Get Alert |
08/01/2024 | Buy Now | 45.17% | Piper Sandler | Matt O'Brien54% | $95 → $80 | Maintains | Overweight | Get Alert |
08/01/2024 | Buy Now | 37.91% | Stifel | Rick Wise63% | $88 → $76 | Maintains | Buy | Get Alert |
08/01/2024 | Buy Now | 28.84% | Wells Fargo | Vik Chopra44% | $77 → $71 | Maintains | Equal-Weight | Get Alert |
08/01/2024 | Buy Now | 76.02% | Needham | Mike Matson70% | $106 → $97 | Maintains | Buy | Get Alert |
07/25/2024 | Buy Now | 92.35% | Needham | Mike Matson70% | $107 → $106 | Maintains | Buy | Get Alert |
05/06/2024 | Buy Now | 94.17% | Needham | Mike Matson70% | $107 → $107 | Reiterates | Buy → Buy | Get Alert |
04/25/2024 | Buy Now | 36.1% | JP Morgan | Robbie Marcus66% | $115 → $75 | Maintains | Overweight | Get Alert |
04/25/2024 | Buy Now | 39.73% | Wells Fargo | Vik Chopra44% | $98 → $77 | Maintains | Equal-Weight | Get Alert |
04/25/2024 | Buy Now | 72.39% | Piper Sandler | Matt O'Brien54% | $100 → $95 | Maintains | Overweight | Get Alert |
04/25/2024 | Buy Now | 94.17% | Needham | Mike Matson70% | $129 → $107 | Maintains | Buy | Get Alert |
02/01/2024 | Buy Now | 81.47% | Piper Sandler | Matt O'Brien54% | $130 → $100 | Maintains | Overweight | Get Alert |
02/01/2024 | Buy Now | 108.68% | JP Morgan | Robbie Marcus66% | $135 → $115 | Maintains | Overweight | Get Alert |
02/01/2024 | Buy Now | 77.84% | Wells Fargo | Durgesh Chopra69% | $107 → $98 | Maintains | Equal-Weight | Get Alert |
02/01/2024 | Buy Now | 134.09% | Needham | Mike Matson70% | $119 → $129 | Maintains | Buy | Get Alert |
10/27/2023 | Buy Now | 135.9% | Piper Sandler | Matt O'Brien54% | $145 → $130 | Maintains | Overweight | Get Alert |
10/26/2023 | Buy Now | 117.76% | Stifel | Rick Wise63% | $136 → $120 | Maintains | Buy | Get Alert |
10/26/2023 | Buy Now | 94.17% | Wells Fargo | Durgesh Chopra69% | $123 → $107 | Maintains | Equal-Weight | Get Alert |
10/26/2023 | Buy Now | 115.94% | Needham | Mike Matson70% | $140 → $119 | Maintains | Buy | Get Alert |
07/27/2023 | Buy Now | 163.12% | JP Morgan | Robbie Marcus66% | $125 → $145 | Maintains | Overweight | Get Alert |
07/27/2023 | Buy Now | 154.05% | Needham | Mike Matson70% | $139 → $140 | Maintains | Buy | Get Alert |
07/27/2023 | Buy Now | 155.87% | Keybanc | Matthew Mishan53% | $131 → $141 | Maintains | Overweight | Get Alert |
07/24/2023 | Buy Now | 152.24% | Needham | Mike Matson70% | → $139 | Reiterates | Buy → Buy | Get Alert |
06/05/2023 | Buy Now | 152.24% | Needham | Mike Matson70% | $135 → $139 | Maintains | Buy | Get Alert |
05/22/2023 | Buy Now | 154.05% | CL King | Kristen Stewart52% | → $140 | Initiates | → Buy | Get Alert |
04/27/2023 | Buy Now | 135.9% | Stifel | Rick Wise63% | $118 → $130 | Maintains | Buy | Get Alert |
04/27/2023 | Buy Now | 132.28% | Piper Sandler | Matt O'Brien54% | $118 → $128 | Maintains | Overweight | Get Alert |
04/27/2023 | Buy Now | 115.94% | Wells Fargo | Durgesh Chopra69% | $96 → $119 | Maintains | Equal-Weight | Get Alert |
04/27/2023 | Buy Now | 144.98% | Needham | Mike Matson70% | $122 → $135 | Maintains | Buy | Get Alert |
04/27/2023 | Buy Now | 137.72% | Keybanc | Matthew Mishan53% | $124 → $131 | Maintains | Overweight | Get Alert |
03/27/2023 | Buy Now | 125.02% | Keybanc | Matthew Mishan53% | → $124 | Upgrade | Sector Weight → Overweight | Get Alert |
02/03/2023 | Buy Now | 114.13% | Piper Sandler | Matt O'Brien54% | $108 → $118 | Maintains | Overweight | Get Alert |
02/03/2023 | Buy Now | 121.39% | Needham | Mike Matson70% | $106 → $122 | Maintains | Buy | Get Alert |
11/15/2022 | Buy Now | 92.35% | Needham | Mike Matson70% | $90 → $106 | Maintains | Buy | Get Alert |
10/14/2022 | Buy Now | 63.32% | Needham | Mike Matson70% | $123 → $90 | Maintains | Buy | Get Alert |
10/12/2022 | Buy Now | 54.25% | Jefferies | Matthew Taylor72% | → $85 | Initiates | → Hold | Get Alert |
08/02/2022 | Buy Now | 123.2% | Needham | Mike Matson70% | $127 → $123 | Maintains | Buy | Get Alert |
07/28/2022 | Buy Now | 114.13% | Piper Sandler | Matt O'Brien54% | $160 → $118 | Maintains | Overweight | Get Alert |
07/28/2022 | Buy Now | 130.46% | Needham | Mike Matson70% | $155 → $127 | Maintains | Buy | Get Alert |
06/23/2022 | Buy Now | 99.61% | Stifel | Rick Wise63% | $160 → $110 | Maintains | Buy | Get Alert |
The latest price target for Conmed (NYSE:CNMD) was reported by Needham on June 12, 2025. The analyst firm set a price target for $61.00 expecting CNMD to rise to within 12 months (a possible 10.69% upside). 16 analyst firms have reported ratings in the last year.
The latest analyst rating for Conmed (NYSE:CNMD) was provided by Needham, and Conmed downgraded their hold rating.
The last upgrade for Conmed Corp happened on March 27, 2023 when Keybanc raised their price target to $124. Keybanc previously had a sector weight for Conmed Corp.
The last downgrade for Conmed Corp happened on June 12, 2025 when Needham changed their price target from $61 to $61 for Conmed Corp.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Conmed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Conmed was filed on June 12, 2025 so you should expect the next rating to be made available sometime around June 12, 2026.
While ratings are subjective and will change, the latest Conmed (CNMD) rating was a downgraded with a price target of $61.00 to $61.00. The current price Conmed (CNMD) is trading at is $55.11, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.